COVID-19: Thrombotic Complications and Therapy
Jonathan L. Halperin, MD, discusses the hemostatic abnormalities in hospitalized COVID-19 patients, including impaired fibrinolysis, elevated D-dimers, and inflammatory increase of cytokines—factors which create an increased need for mechanical ventilation and increased mortality. Dr. Halperin describes the progression of COVID-19, and the threat of the complication of both deep vein thrombosis and pulmonary embolism, as well as the impact of lung damage on coagulation. The Mount Sinai panel provides perspectives on effective patient evaluation, management, and antithrombotic strategies.
Published
May 15, 2020
Created by
Featured Faculty
Jeffrey Olin, DO, FACC, FAHA, MSVM
Professor, Medicine (Cardiology)
Director, Vascular Medicine, Zena and Michael A. Wiener Cardiovascular Institute
Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
Icahn School of Medicine at Mount Sinai
The Robert and Harriet Heilbrunn Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
Director of Clinical Cardiology Services, The Zena and Michael A. Wiener Cardiovascular Institute
Mount Sinai Health System
Director of Cardiac Arrhythmia Services
The Mount Sinai Hospital and the Mount Sinai Health System
The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology
Icahn School of Medicine at Mount Sinai
Director, The Zena and Michael Wiener Cardiovascular Institute
Icahn School of Medicine at Mount Sinai
Director, Mount Sinai Heart
Physician-in-Chief
The Mount Sinai Hospital
Professor, Medicine (Hospital Medicine)
Icahn School of Medicine at Mount Sinai
Chief, Division of Hospital Medicine
Mount Sinai Health System
Associate Professor, Medicine (Hematology and Medical Oncology)
Icahn School of Medicine at Mount Sinai
Mount Sinai Beth Israel
New York Eye and Ear Infirmary of Mount Sinai
Mount Sinai Morningside and Mount Sinai West